Plant drugs in kidney diseases. more harm than benefit?
Stiefelhagen, P.
MMW Fortschritte der Medizin 147(8): 10
2005
ISSN/ISBN: 1438-3276 PMID: 18441556 Document Number: 590763
Document emailed within 1 workday
Related Documents
Fenner, H. 1992: Nonsteroidal antiinflammatory drugs: benefit/risk evaluation in rheumatic diseases Journal of Rheumatology. Suppl 32: 98-99Vogel, G. 1983: Drugs of plant origin used in liver diseases Zfa. Zeitschrift für Allgemeinmedizin 59(24): 1296-1303
2013: Ivacaftor. Uncertain harm-benefit balance Prescrire international 22(142): 229-231
Einecke, D. 2006: Stable coronary disease patients: more harm than benefit from heart catheter? MMW Fortschritte der Medizin 148(38): 12-14
Musa, J. 2011: Withholding breast milk for HIV exposed infants in sub-Saharan Africa: benefit or harm? African Health Sciences 11(4): 602-604
2014: Oncology and haematology in 2013. Some advances, but too many new treatments with an inadequately assessed harm-benefit balance Prescrire International 23(148): 103-105
Andreev, I.; Chukanov, K.; Tishkov, I.; Stefanova, G.; Khausvald, I. 1974: Therapeutic results of immunologic kidney diseases treated with immunosuppressive drugs Vutreshni Bolesti 13(3): 77-86
Edelman, A. 2015: Teens and young adults should be started on long-acting reversible contraceptives before sexual activity commences: AGAINST: Pre-emptive use without need or benefit may cause more harm than good Bjog: An International Journal of Obstetrics and Gynaecology 122(8): 1052
Edelman, A. 2015: Teens and young adults should be started on long-acting reversible contraceptives before sexual activity commences: AGAINST: Pre-emptive use without need or benefit may cause more harm than good Bjog: An International Journal of Obstetrics and Gynaecology 122(8): 1052
Jourdan, M. 2009: Casting light on harm reduction: introducing two instruments for analysing contradictions between harm reduction and 'non-harm reduction' International Journal on Drug Policy 20(6): 514-520
Jourdan, M. 2009: Casting light on harm reduction: introducing two instruments for analysing contradictions between harm reduction and 'non-harm reduction' International Journal on Drug Policy 20(6): 514-520
Ennet, D.; Hauschild, J.; Pank, F. 1978: Residues of plant protection products and agents for controlling biological processes in drugs of the pharmacopoeia of the GDR, edition 2. 1. General aspects of packaging of plant protection products and agents for controlling biological processes in botanical drugs in the GDR Die Pharmazie 33(11): 697-705
Gossell-Williams, M. 2010: Pharmacovigilance: healthcare professionals' role in benefits versus harm analysis of drugs use West Indian Medical Journal 59(1): 73-75
Naisteter, M.A.; Sitron, J.A. 2010: Minimizing Harm and Maximizing Pleasure: Considering the Harm Reduction Paradigm for Sexuality Education American Journal of Sexuality Education 5(2): 101-115
Dimick, C. 2010: No harm done? Assessing risk of harm under the federal breach notification rule Journal of Ahima 81(8): 20-25
Dimick, C. 2010: No harm done? Assessing risk of harm under the federal breach notification rule Journal of Ahima 81(8): 20-25
Locatelli, F.; Del Vecchio, L.; La Milia, V. 2016: The use of drugs in chronic renal insufficiency: primum non nocere! (First do not harm!). the paradigmatic cases of azathioprine, metformin and denosumab Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 33(5)
Schulz, V.; Ulmer, W.T.; Kleinsorge, H. 1992: Risk-benefit assessment and value of beta-2-sympathomimetic drugs in asthma therapy Pneumologie 46(8): 315-321
Hensley, S. 1998: New drugs blast budgets. Patients benefit; hospital pharmacies weigh options Modern Healthcare 28(23): 36
Richards, R.; Burls, A.; Payne, N. 2000: Cost utility of drugs for multiple sclerosis. Methods used don't calculate true benefit Bmj 320(7247): 1475; Author Reply 1475-6